Login / Signup

Author response to Colle et al.

Giovanni FucàFrancesca CortiFilippo Pietrantonio
Published in: Journal for immunotherapy of cancer (2021)
The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, with early assessments being associated with higher incidence. Such dynamics should be considered when interpreting the efficacy of treatment.
Keyphrases
  • metastatic colorectal cancer
  • risk factors
  • combination therapy
  • replacement therapy